Estimating the burden of nosocomial exposure to tuberculosis in South Korea, a nationwide population based cross-sectional study

Hyung Woo Kim; Jun-Pyo Myong; Ju Sang Kim

doi:10.3904/kjim.2020.144

Korean J Intern Med > Volume 36(5); 2021 > Article

Kim, Myong, and Kim: Estimating the burden of nosocomial exposure to tuberculosis in South Korea, a nationwide population based cross-sectional study

Original Article

Pulmonology

The Korean Journal of Internal Medicine 2021;36(5):1134-1145.

Published online: December 18, 2020

DOI: https://doi.org/10.3904/kjim.2020.144

Estimating the burden of nosocomial exposure to tuberculosis in South Korea, a nationwide population based cross-sectional study

Hyung Woo Kim¹, Jun-Pyo Myong², Ju Sang Kim¹

¹Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Incheon St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea

²Department of Occupational and Environmental Medicine, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea

Correspondence to: Ju Sang Kim, M.D., Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Incheon St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, 56 Dongsu-ro, Bupyeong-gu, Incheon 21431, Korea, Tel: +82-32-280-5749, Fax: +82-32-280-5196, E-mail: kimjusang@catholic.ac.kr

Received April 8, 2020 Revised April 28, 2020 Accepted May 1, 2020

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

See editorial "Nosocomial exposure to tuberculosis: a snapshot of South Korea" on page 1061.

Abstract

Background/Aims

The aim of the study was to investigate the current nationwide burden of nosocomial exposure to tuberculosis (TB) using national health insurance claims data.

Methods

All patients who had claims for drug susceptibility testing for TB from 2012 to 2016, which indicated culture-proven TB, were included. The first day of the infectious period was defined as 3 months before a doctor’s suspicion of TB in patients with respiratory symptoms and 1 month before in patients without symptoms. The last day of the infectious period was defined as one day before the prescription of anti-TB medications. Patients hospitalized during infectious periods were investigated and their hospitalization days were calculated. Records of medical procedures which increased the risk of nosocomial transmission by generating aerosols were also investigated.

Results

A total of 7,186 cases with 94,636 person-days of hospitalization with unrecognized active TB were found. Patients above 60 years of age accounted for 63.99% of the total number and 69.70% of the total duration of hospitalization. TB patients in the older age group showed a trend toward higher risks for hospitalization with unrecognized active TB. Patients in their 80s showed the highest risk (12.65%). Bronchoscopy (28.86%), nebulizer therapy (28.48%), and endotracheal intubation (13.02%) were common procedures performed in these patients during hospitalization.

Conclusions

The burden of nosocomial exposure to TB in South Korea is still substantial. Hospitalization with unrecognized active TB, especially among the elderly TB patients could be a serious public health issue in South Korea.

Keywords: Pulmonary tuberculosis; Nosocomial infection; Infectious disease transmission; Epidemiology; Korea

Graphical abstract

INTRODUCTION

South Korea is a country with an intermediate tuberculosis (TB) burden. The incidence rate was 66 cases per 100,000 population in 2018 [1]. The burden of TB in South Korea is disproportionately high considering the nation’s sociodemographic index, an indicator reflecting income, education level, and fertility rate [2]. One reason for the high TB burden is the high incidence of TB in the elderly population [3,4]. Although the total incidence of TB is decreasing, the number of reported cases and the proportion of TB in the elderly is rising, from 6,547 new TB cases out of 34,123 total cases (19.2%) in 2001 to 14,193 cases out of 30,304 total cases (46.8%) in 2019 [5]. Elderly TB patients often present with atypical symptoms, so the diagnosis of TB can be delayed [6–8]. They also show atypical radiologic manifestations, misdiagnosed as pneumonia [9,10], and often need hospitalization indicated by CURB-65 (confusion, urea, respiratory rate, blood pressure, age ≥ 65) scores.

As hospitals are overcrowded, the risk of TB transmission is higher than in the community [11–13]. Moreover, the delay in a TB diagnosis in hospitalized patients can lead to a nosocomial TB outbreak [14–16]. In a population based TB investigation using molecular epidemiological techniques, a substantial proportion of TB transmissions occurred in hospitals [17]. The hospital environment in South Korea is especially vulnerable to the transmission of respiratory infections, which was one of the reasons for the Middle East respiratory syndrome outbreak in 2015. More than 50% of the wardrooms in South Korea are multiple occupancies with more than four beds per room and the rooms are overcrowded with family members of patients or privately hired aides who take care of the patients [18].

National Institute for Health and Care Excellence guidelines recommend that patients who spent more than 8 hours in the same wardroom with a smear-positive TB patient with a cough should be considered at risk for infection [19]. Several studies have reported that even smear-negative TB patients were infectious [20,21]. In Europe, close non-household contact is defined as those persons with a cumulative exposure time of 40 hours with sputum culture-positive TB patients, regardless of smear results [22]. Therefore, nosocomial transmission can result from smear-negative but culture-positive TB patients who are unexpectedly diagnosed with TB from the results of sputum or bronchial washing fluid cultures reported several weeks later [23,24].

The present study aimed to investigate the current nationwide burden of nosocomial exposure to TB using national health insurance claims data.

METHODS

Data sources

Nationwide data collected between 2007 and 2016 derived from the Korean Health Insurance Review and Assessment (HIRA) database was analyzed. National health insurance in Korea is a mandatory program with universal health coverage system that covers almost 98% of the Korean population [25]. The HIRA database provides sociodemographic information on the insured, diagnoses described with International Classification of Diseases, 10th Revision (ICD-10) codes, and drugs, diagnostic examinations, and therapeutic procedures ordered by medical doctors.

Definition of pulmonary TB

To estimate the minimal burden of TB exposure, only culture-proven TB patients were included. Because the culture results were unavailable in the claims data, an operational definition of at least one prescription record for phenotypic drug susceptibility testing (DST) was used. Since 2005, the Korean TB guidelines have recommended that all TB patients undergo DST with the first culture-positive specimen [26]. However, the actual prescription rate for DST among culture-proven TB patients was suboptimal [27]. Since the introduction of private-public mix (PPM) in 2007 and nationwide expansion in 2011, the continuous monitoring of clinical practice by PPM nurses raised prescription rate for DST to a current level. Therefore, only patients who were diagnosed with TB from 2012 to 2016 were finally included to avoid underestimation of TB cases due to suboptimal prescription rates for DST. The records of individuals with ICD-10 codes of pulmonary TB (A15, A16, or A19) in addition to prescription records of phenotypic DST between 2007 to 2016 were extracted from HIRA database.

To estimate the actual burden of TB exposure, multiple episodes of treatment in a TB patient were analyzed as separate cases, if only DST was prescribed in treatment period. To define culture-confirmed TB cases, the operational definition of ‘treatment case’ and ‘DST case’ were used. All prescription records of at least three anti-TB medications (rifampin, rifabutin, isoniazid, ethambutol, pyrazinamide, kanamycin or streptomycin, levofloxacin or moxifloxacin, prothionamide, cycloserine, para-aminosalicylic acid) in each TB patient were sorted in time order, and any consecutive records with more than 180 days of interval were defined as separate ‘treatment case.’ Likewise, prescription records of DST in each TB patient were sorted, and any consecutive records with more than 90 days of interval were defined as separate ‘DST case.’ After applying clearing period of 2007 to treatment cases, incident treatment cases between 2008 to 2016 were identified. Then, treatment cases and DST cases were matched in each TB patients, and only cases with prescription records of DST within 6 months after treatment initiation were defined as culture-confirmed pulmonary TB cases. For a reason that described above, only cases from 2012 to 2016 were included in this study, finally (Fig. 1).

Definition of infectious period

Although there is no method to determine the start day of an infectious period, the Center for Disease Control and Prevention recommends the practical estimation of the start day by TB symptoms, smear results, and the presence of a cavity on chest X-ray [28]. Because the results of smears and chest X rays were not available in the claims data, a simple operational definition was used. The date of TB diagnosis (Point C) was defined as the time point when at least three kinds of anti-TB medication were first prescribed (Fig. 2). The timepoint of the clinician’s first suspicion of TB (Point B) was defined as the date when TB-specific examinations (acid-fast bacilli smear, culture, nucleic acid amplification tests) were first ordered. For patients with prescription records of antitussive or mucolytic medications within 3 months before Point B, the first day of the infectious period (Point A) was defined as 90 days before Point B. For patients without those prescriptions, the Point A was defined as 30 days before. The last day of the infectious period was defined as one day before Point C. Though at least 2 weeks of anti-TB treatment is needed to be non-infectious, as mentioned in Korean guidelines for TB [29], in our study, confirmed TB patients were regarded as non-infectious, as they were isolated immediately after diagnosis of TB. The time interval between Point B and Point C was defined as the ‘healthcare system delay.’ Any hospitalizations during the infectious periods were totaled as person-days. There may be hospitalizations in isolated room before initiation of anti-TB treatment, in cases of suspected TB. Therefore, claims records for a charge for use of an isolation room during the infectious period were also investigated. Isolated hospitalization days were subtracted from the total hospitalization days during the infectious period, which defined hospitalization with unrecognized TB.

Data collection

For external validation of total number of extracted TB cases from HIRA database, the total identified cases were sorted by year of diagnosis and compared with annual cases reported by the Korean government, and those estimated by the World Health Organization (WHO). To investigate the clinical characteristics of TB patients hospitalized during infectious periods, comorbidities expressed by ICD-10 codes in the claims data were compared between hospitalized patients and those not hospitalized. The Charlson comorbidity index (CCI) was used as a tool to describe the comorbidities [30,31]. The 17 comorbidities which comprise CCI were defined with ICD-10 codes presented in Supplementary Table 1. Patients with more than three claim records with specific ICD-10 codes representing each comorbidity within 2 years before TB diagnosis were considered as having that comorbidity. The total number of hospitalizations with unrecognized TB and their person-days were analyzed in each age group. Records of medical procedures which increase the risk of nosocomial transmission by generating aerosols—bronchoscopy, laryngoscopy, endotracheal intubation, tracheostomy, cardiopulmonary resuscitation, use of a nebulizer, use of a high flow oxygen cannula, or mechanical ventilation—were investigated among the cases. Those performed during intensive care unit (ICU) admissions were counted separately.

Statistical analysis

For continuous variables, independent t tests or the Wilcoxon rank sum test were used for comparison. For categorical variables, the chi-square test or Fisher’s exact test was used. Trends across ordinal variables were tested with the Cochran-Armitage test for trend. A p < 0.05 was considered to be statistically significant. Statistical analyses were performed with SAS software version 9.4 (SAS Institute Inc., Cary, NC, USA).

Ethics statements

Ethics approval was obtained from the Institutional Review Board of Incheon St. Mary’s Hospital, Incheon, Korea (IRB No. OC17ZESE0085). The requirement for informed consent was waived by the Board.

RESULTS

From 2012 to 2016, a total of 92,692 cases of culture-proven pulmonary TB cases were identified (Fig. 1). The total number of extracted cases sorted by year of diagnosis, nationally-reported pulmonary TB cases [5], and bacteriologically confirmed pulmonary TB cases reported by WHO [1] were compared (Table 1).

The median infectious period of the total identified cases (n = 92,692) was 90 days (interquartile range [IQR], 90 to 98). That of patients with respiratory symptoms (n = 69,745) and without symptoms (n = 22,947) were 92 days (IQR, 90 to 104) and 34 days (IQR, 30 to 47) The healthcare system delays of patients hospitalized (n = 7,714) and those not hospitalized (n = 84,978) were compared (Fig. 3). The median healthcare system delay in the hospitalized cases was 23 days (IQR, 3 to 60), which was longer than that of those not hospitalized (2 days; IQR, 0 to 12; p < 0.001).

Characteristics of TB patients hospitalized during the infectious period

A total of 7,714 cases with 108,631 person-days of hospitalization during the infectious period was identified between 2012 to 2016. The mean age of the hospitalized group was higher than the non-hospitalized group (p < 0.001) and the proportion of males was lower in the hospitalized group (p = 0.009) (Table 2). The mean total CCI scores of the hospitalized group was higher than the non-hospitalized group (p < 0.001), implying that chronic diseases were more prevalent in the hospitalized group. In all comorbidities except ‘any tumor’ and ‘acquired immune deficiency syndrome,’ hospitalized patients showed a higher prevalence than non-hospitalized patients.

Burden of nosocomial exposure to pulmonary TB

After excluding cases with admissions to an isolation room, a total 7,186 cases with 94,636 person-days of hospitalization with unrecognized TB, which represented the nationwide burden of nosocomial exposure to TB, were identified. When the cases were classified into age groups, groups above 60 years of age accounted for 63.99% of the total number and 69.70% of the total duration of hospitalizations with unrecognized TB (Table 3). Patients in the older age group (p < 0.001) showed a trend toward a higher risk for hospitalization with unrecognized TB. The highest risk was noted in TB patients in their 80s (12.65%), which implies that among the culture-positive pulmonary TB patients in their 80s, 12.65% of patients were hospitalized without awareness of an active TB.

In the analysis of high-risk procedures, the most common procedures performed during hospitalization in infectious periods were bronchoscopies (28.86%) and nebulizer therapy (28.48%) (Table 4). When the cases were confined to hospitalization in the ICU, the proportion of patients who underwent high-risk procedures increased in all procedures, except bronchoscopy and laryngoscopy, suggesting that the ICU was a more vulnerable place for the nosocomial transmission of TB than general wards.

DISCUSSION

In this study, the nationwide burden of nosocomial exposure to TB in South Korea was estimated. Hospitalized patients were older and had more comorbidities compared to those not hospitalized. Elderly TB patients accounted for a substantial proportion of that burden, which demonstrated that TB in the elderly is a serious public health issue in South Korea.

Previous studies regarding the nosocomial transmission of TB in South Korea have focused on latent tuberculosis infections (LTBI) only in healthcare workers [32–35]. In a recently published study covering the results of an expanded contact investigation, which included inpatients and visitors, more close contacts were identified among them than among the healthcare workers [36]. Korean guidelines for national tuberculosis control recommend that contact investigations in nosocomial settings are needed when active TB in healthcare workers is identified [37]. Therefore, when inpatients are diagnosed with TB later during hospitalization, contact investigation of other inpatients and hospital visitors is not obligatory in South Korea. Lately, a few hospitals have initiated expanded contact investigation programs, including inpatients and visitors. However, considering the high LTBI prevalence in South Korea [38], diagnostic tests for LTBI have limited roles in demonstrating recent infections.

One of the epidemiologic features of TB in South Korea is the generation gap in the TB burden. As the incidence of TB in the younger generation decreases and TB in the elderly with various comorbidities increases [4–6], hospitals could be a major place for TB transmission, as in Japan [17]. The results of our study support that possibility. Elderly TB patients accounted for 64% of total burden of nosocomial TB exposure. Prevalence of unrecognized hospitalization was more than 10% among the elderly TB patients, which was higher than that in younger TB patients.

In addition to diagnostic difficulties which result from atypical clinical presentations and radiologic features among elderly TB patients, poor adherence to anti-TB treatment is also an important public health issue in elderly TB patients [39]. Higher risk for experiencing adverse effects in elderly TB patients may be a reason for their poor adherence [40,41]. Also, mortality rate among elderly TB patients was high in South Korea—up to 26% in those age 75 or older in a citywide study [42]. In these backgrounds, management of elderly TB became one of key strategies of national TB control program in South Korea [38]. Pilot projects of active case finding among elderly population were implemented in 2017, which can reduce the current abundant burden of nosocomial TB exposure through early detection of elderly TB patients [43]. In addition, though it is not feasible so far [44], strategies of screening and treatment of LTBI among the elderly population have been investigated [45].

In several studies recently published in South Korea, hospitalization to a department other than a pulmonology or infectious diseases department, suggesting non-respiratory related hospitalization was a significant risk factor delayed isolation of hospitalized TB patients [46–48]. In those studies, more comorbidities such as malignancy, cardiovascular disease, chronic kidney disease were identified among the delayed isolation groups. Although the main reason for hospitalization were not investigated in our study, a substantial proportion of those hospitalizations might be attributable to non-respiratory related hospitalization associated with their comorbidities. Moreover, in previous studies mentioned above, typical symptoms of pulmonary TB were less prominent among the delayed group. These factors may bring about low index of suspicion for TB among physicians.

For a long time, chest X-ray has been used as a screening tool for TB. Although there are limitations of chest X-ray as a screening tool [49], it is noteworthy that approximately half of delayed cases were diagnosed with chest radiographs retrospectively interpreted by radiologists, in the previous study [48]. Recently developed automatic detection algorithm using artificial intelligence can be a useful tool for early detection of TB [50], when combined with automatic alarming systems reporting to physicians. Further studies investigating whether those new tools can shorten the healthcare system delay of TB diagnosis are needed.

Xpert MTB/RIF assay which was introduced to South Korea in 2013 provides faster, more accurate results than smear microscopy [51]. In our study, median time from physicians’ suspicion of TB to prescription of anti-TB medication was only 2 days (IQR, 0 to 15) among the total cases, which might reflect the widespread use of Xpert MTB/RIF assay. However, as elderly TB patients often have difficulty in producing adequate sputum specimens [52], new diagnostic tools complementary to sputum-based diagnosis should be investigated, considering increasing proportion of the elderly TB patients. Currently investigated diagnostic methods using serum or plasma which detect components of Mycobacterium tuberculosis (Mtb) or host immune response to Mtb may be useful especially among the elderly TB patients [53].

The proportion of patients who underwent bronchoscopies during hospitalization with unrecognized TB was 28.86%, which was compatible with previous reports in South Korea [54]. Bronchoscopy is not a routine method for diagnosing TB, but our results showed that bronchoscopies were frequently performed in TB patients in South Korea. In a previous study, approximately 4.6% of the patients who underwent bronchoscopies after computed tomography scans for diagnosis pulmonary disease other than TB, were eventually and unexpectedly, diagnosed with TB [23]. Another remarkable finding was that records of endotracheal intubations were identified in 1,004 cases (13.02%) among total hospitalized cases. In general, endotracheal intubation is performed to protect the patency of airway in situations of clinical deterioration, or electively before general anesthesia. In our study, among 1,004 cases (13.02%), 374 cases (4.85%) were the former and 630 cases (8.17%) were the latter. These 630 cases might represent the burden of nosocomial exposure to TB in operating rooms.

The claims data has several strengths. Exact timepoints, such as the date of admission, outpatient visits, and prescriptions for anti-TB medication or diagnostic examinations could be identified without bias. In contrast to hospital-based cohort studies, in which the medical records in participating institutions are collected, all records of medical utilization in the country were included in this population-based cohort study using claims data. A limitation of our study was that information on the infectivity of the index cases (smear status and presence of pulmonary cavity) was unavailable in the claims data. To overcome this limitation, only pulmonary TB patients with records of DST, meaning culture-proven TB cases, were included in this study. Although a consensus definition was used, the uncertainty of the exact infectious period remains a limitation of this study. In addition, the primary endpoint of this study was the burden of nosocomial TB exposure, not actual transmission. Further studies on transmission in nosocomial settings are needed.

In conclusion, the burden of nosocomial exposure to TB in South Korea was still substantial. As the proportion of elderly TB patients increases, hospitals could be the most important place for TB transmission in the near future. Comprehensive national TB control programs to reduce the nosocomial transmission of TB should be implemented.

KEY MESSAGE

1. Total burden of nosocomial exposure to tuberculosis (TB)–7,186 cases with 94,636 person-days of hospitalization with unrecognized TB between 2012 to 2016 were identified.

2. TB patients who were hospitalized during infectious period were elder and had more comorbidities than those who were not.

3. High-risk medical procedures for TB transmission were performed frequently, especially in intensive care unit.

Conflict of Interest

No potential conflict of interest relevant to this article was reported.

Acknowledgments

The authors thank Jun Choi (former graduate student of Korea University) for contribution in data clearing and analysis.

Supplementary Materials

Supplementary Table 1.

ICD-10 codes representing each category of Charlson comorbidity index

kjim-2020-144-suppl.pdf

Figure 1

Flow chart of cases included in this study from the national health insurance claims data. Treatment case was defined with prescription records of at least three anti-tuberculosis (TB) medications. Any consecutive prescription records with more than 180 days of interval were defined as separate treatment cases. Likewise, drug susceptibility testing (DST) cases was defined with prescription records of DST. Any consecutive prescription records with more than 90 days of interval were defined as separate DST cases. After applying clearing period of 2007 to treatment cases, treatment cases and DST cases were matched in each TB patients, and only cases with prescription records of DST within 6 months after treatment initiation were defined as culture-confirmed pulmonary TB cases.

Figure 2

Operational definition of infectious period. The infectious period was defined as the term between Point A (presumed timepoint that the first transmission of Mycobacterium occurred) and a day before Point C (day of initiation of anti-tuberculosis [TB] medication). Healthcare system delay was defined as the interval between Point B (the first day when the clinical doctor suspected TB) and Point C. ICD-10, International Classification of Diseases, 10th Revision; DST, drug susceptibility testing.

Figure 3

Density plots of healthcare system delays in hospitalization group (hosp) and non-hospitalization group (non-hosp). Dashed line represents median healthcare system delay 23 days in hospitalization group, whereas 2 days in non-hospitalization group.

Table 1

Comparison between cases identified, total national reported cases and bacteriologically confirmed cases estimated by WHO

Year	No. of cases identified	National notified pulmonary TB cases	TB cases estimated by WHOa
2012	19,261	31,075	28,397
2013	19,290	28,720	21,817
2014	19,266	27,906	21,489
2015	18,144	25,550	20,055
2016	16,731	24,696	20,072
Total	92,692	137,947	111,830

WHO, World Health Organization; TB, tuberculosis.

^a Bacteriologically confirmed pulmonary TB cases (smear-positive or culture-positive or positive by WHO-recommended rapid diagnostic tests) which includes both new and relapsed cases.

Table 2

Characteristics and comorbidities of culture-proven pulmonary TB cases with and without hospitalization during the infectious period

Characteristic	Hospitalization (n = 7,714)	Non-hospitalization (n = 84,978)	p value
Age, yr	64.50 ± 16.78	56.08 ± 19.84	< 0.001
Male sex	4,618 (59.87)	52,154 (61.37)	0.009
Total CCI score	2.98 ± 2.56	2.04 ± 2.16	< 0.001
Categories of CCI
Respiratory diseases
Chronic pulmonary disease	3,021(39.16)	28,080 (33.04)	< 0.001
Cardiovascular diseases
Myocardial infarction	315 (4.08)	1,666 (1.96)	< 0.001
Congestive heart failure	1,379 (17.88)	7,656 (9.01)	< 0.001
Peripheral vascular disease	204 (2.64)	1,344 (1.58)	< 0.001
Malignant neoplasms
Any malignancy, including lymphoma and leukemia	298 (3.86)	3,094 (3.64)	0.320
Metastatic solid tumor	560 (7.26)	3,179 (3.74)	< 0.001
Endocrine diseases
Diabetes without chronic complication	4,405 (57.10)	35,122 (41.33)	< 0.001
Diabetes with chronic complication	813 (10.54)	5,851 (6.89)	< 0.001
Renal diseases
Renal disease	255 (3.31)	1,508 (1.77)	< 0.001
Gastrointestinal diseases
Peptic ulcer disease	491 (6.37)	3,833 (4.51)	< 0.001
Mild liver disease	4,940 (64.04)	44,519 (52.39)	< 0.001
Moderate or severe liver disease	119 (1.54)	654 (0.77)	< 0.001
Psychological diseases
Dementia	759 (9.84)	3,428 (4.03)	< 0.001
Neurological diseases
Cerebrovascular disease	98 (1.27)	667 (0.78)	< 0.001
Hemiplegia or paraplegia	313 (4.06)	1,471 (1.73)	< 0.001
Musculoskeletal and connective tissue diseases
Connective tissue disease	157 (2.04)	1,140 (1.34)	< 0.001
Infectious diseases
AIDS	20 (0.26)	225 (0.26)	0.928

Values are presented as mean ± SD deviation or number (%).

TB, tuberculosis; CCI, Charlson comorbidity index; AIDS, acquired immune deficiency syndrome.

Table 3

Hospitalization with unrecognized tuberculosis by age group

Age, yr	Total cases	No. of cases with unrecognized hospitalization	Sum of unrecognized hospitalization, person-day	Prevalence of unrecognized hospitalization, %	Unrecognized hospitalization, day
< 10	39	0	0	0	0
10–19	2,544	73 (1.02)	493 (0.52)	2.87	6.75 ± 3.44
20–39	8,821	268 (3.73)	1,776 (1.88)	3.04	6.63 ± 3.71
30–39	9,597	381 (5.30)	3,337 (3.53)	3.97	8.76 ± 8.16
40–49	13,081	724 (10.08)	8,240 (8.71)	5.53	11.38 ± 10.69
50–59	16,203	1,142 (15.89)	14,830 (15.67)	7.05	12.99 ± 12.88
60–69	13,886	1,321 (18.38)	19,117 (20.20)	9.51	14.47 ± 15.16
70–79	19,232	2,108 (29.33)	31,898 (33.71)	10.96	15.13 ± 15.95
80–89	8,538	1,080 (15.03)	13,921 (14.71)	12.65	12.89 ± 15.69
≥ 90	751	89 (1.24)	1,024 (1.08)	11.85	11.51 ± 14.45
Total	92,692	7,186 (100.00)	94,636 (100.00)	7.75	13.17 ± 14.26

Values are presented as number (%) or mean ± SD.

Table 4

High-risk procedures performed during hospitalization in infectious periods

Variable	Total hospitalizationa (n = 7,714)	Hospitalization in ICU (n = 2,263)
Bronchoscopy	2,226 (28.86)	561 (24.79)
Laryngoscopy	317 (4.11)	73 (3.23)
Endotracheal intubation	1,004 (13.02)	365 (16.13)
Tracheostomy	74 (0.96)	65 (2.87)
Cardiopulmonary resuscitation	19 (0.25)	12 (0.53)
Nebulizer therapy	2,197 (28.48)	948 (41.89)
High flow oxygen cannula	31 (0.40)	26 (1.15)
Mechanical ventilation	447 (5.79)	368 (16.26)

Values are presented as number (%).

ICU, intensive care unit.

^a Hospitalizations in ICU were included.

REFERENCES

1. World Health Organization. Global Tuberculosis Report 2019. Geneva (CH): WHO, 2019.

2. GBD Tuberculosis Collaborators. Global, regional, and national burden of tuberculosis, 1990–2016: results from the Global Burden of Diseases, Injuries, and Risk Factors 2016 Study. Lancet Infect Dis 2018;18:1329–1349.

3. Kim JH, Yim JJ. Achievements in and challenges of tuberculosis control in South Korea. Emerg Infect Dis 2015;21:1913–1920.

4. Park YK, Park YS, Na KI, Cho EH, Shin SS, Kim HJ. Increased tuberculosis burden due to demographic transition in Korea from 2001 to 2010. Tuberc Respir Dis (Seoul) 2013;74:104–110.

5. Korea Centers for Disease Control and Prevention. Annual Report on the Notified Tuberculosis in Korea, 2019. Cheongju (KR): KCDC, 2020.

6. Rajagopalan S. Tuberculosis and aging: a global health problem. Clin Infect Dis 2001;33:1034–1039.

7. Rajagopalan S, Yoshikawa TT. Tuberculosis in the elderly. Z Gerontol Geriatr 2000;33:374–380.

8. Zevallos M, Justman JE. Tuberculosis in the elderly. Clin Geriatr Med 2003;19:121–138.

9. Lee JH, Han DH, Song JW, Chung HS. Diagnostic and therapeutic problems of pulmonary tuberculosis in elderly patients. J Korean Med Sci 2005;20:784–789.

10. Nakao M, Sone K, Kagawa Y, et al. Diagnostic delay of pulmonary tuberculosis in patients with acute respiratory distress syndrome associated with aspiration pneumonia: two case reports and a mini-review from Japan. Exp Ther Med 2016;12:835–839.

11. Jenkins HE, Crudu V, Soltan V, Ciobanu A, Domente L, Cohen T. High risk and rapid appearance of multidrug resistance during tuberculosis treatment in Moldova. Eur Respir J 2014;43:1132–1141.

12. Crudu V, Merker M, Lange C, et al. Nosocomial transmission of multidrug-resistant tuberculosis. Int J Tuberc Lung Dis 2015;19:1520–1523.

13. Escombe AR, Huaroto L, Ticona E, et al. Tuberculosis transmission risk and infection control in a hospital emergency department in Lima, Peru. Int J Tuberc Lung Dis 2010;14:1120–1126.

14. Harris TG, Sullivan Meissner J, Proops D. Delay in diagnosis leading to nosocomial transmission of tuberculosis at a New York City health care facility. Am J Infect Control 2013;41:155–160.

15. Greenaway C, Menzies D, Fanning A, et al. Delay in diagnosis among hospitalized patients with active tuberculosis: predictors and outcomes. Am J Respir Crit Care Med 2002;165:927–933.

16. Wang JY, Lee MC, Chang JH, et al. Mycobacterium tuberculosis nucleic acid amplification tests reduce nosocomial tuberculosis exposure in intensive care units: a nationwide cohort study. Respirology 2015;20:1233–1240.

17. Seto J, Wada T, Suzuki Y, et al. Mycobacterium tuberculosis transmission among elderly persons, Yamagata prefecture, Japan, 2009–2015. Emerg Infect Dis 2017;23:448–455.

18. Ki M. 2015 MERS outbreak in Korea: hospital-to-hospital transmission. Epidemiol Health 2015;37:e2015033.

19. National Institute for Health and Clinical Excellence. Tuberculosis (NICE guideline 33) [Internet] London (UK): NICE, c2020. [cited 2020 Nov 5]. Available from: https://www.nice.org.uk/guidance/ng33 .

20. Paranjothy S, Eisenhut M, Lilley M, et al. Extensive transmission of Mycobacterium tuberculosis from 9 year old child with pulmonary tuberculosis and negative sputum smear. BMJ 2008;337:a1184.

21. Tostmann A, Kik SV, Kalisvaart NA, et al. Tuberculosis transmission by patients with smear-negative pulmonary tuberculosis in a large cohort in the Netherlands. Clin Infect Dis 2008;47:1135–1142.

22. Erkens CG, Kamphorst M, Abubakar I, et al. Tuberculosis contact investigation in low prevalence countries: a European consensus. Eur Respir J 2010;36:925–949.

23. Na HJ, Eom JS, Lee G, et al. Exposure to Mycobacterium tuberculosis during flexible bronchoscopy in patients with unexpected pulmonary tuberculosis. PLoS One 2016;11:e0156385.

24. Kim MH, Suh GY, Chung MP, et al. The value of routinely culturing for tuberculosis during bronchoscopies in an intermediate tuberculosis-burden country. Yonsei Med J 2007;48:969–972.

25. Kim JA, Yoon S, Kim LY, Kim DS. Towards actualizing the value potential of Korea Health Insurance Review and Assessment (HIRA) data as a resource for health research: strengths, limitations, applications, and strategies for optimal use of HIRA data. J Korean Med Sci 2017;32:718–728.

26. Korean Academy of Tuberculosis and Respiratory Diseases. Guideline for the Management of Tuberculosis 2005. Seoul (KR): Korean Academy of Tuberculosis and Respiratory Diseases, 2005.

27. Jung YJ, Park IN, Hong SB, et al. The clinical characteristics, diagnosis, treatment, and outcomes of patients with tuberculosis at a private university hospital in Korea. Tuberc Respir Dis 2006;60:194–204.

28. National Tuberculosis Controllers Association; Centers for Disease Control and Prevention (CDC). Guidelines for the investigation of contacts of persons with infectious tuberculosis: recommendations from the National Tuberculosis Controllers Association and CDC. MMWR Recomm Rep 2005;54(RR-15):1–47.

29. Joint Committee for the Revision of Korean Guidelines for Tuberculosis. Korean Guidelines for Tuberculosis. 3rd ed. Cheongju (KR): Korea Centers for Disease Control and Prevention, 2017.

30. Quan H, Sundararajan V, Halfon P, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care 2005;43:1130–1139.

31. Brusselaers N, Lagergren J. The Charlson comorbidity index in registry-based research. Methods Inf Med 2017;56:401–406.

32. Jo KW, Woo JH, Hong Y, et al. Incidence of tuberculosis among health care workers at a private university hospital in South Korea. Int J Tuberc Lung Dis 2008;12:436–440.

33. Lee K, Han MK, Choi HR, et al. Annual incidence of latent tuberculosis infection among newly employed nurses at a tertiary care university hospital. Infect Control Hosp Epidemiol 2009;30:1218–1222.

34. Park HY, Jeon K, Suh GY, et al. Interferon-γ release assay for tuberculosis screening of healthcare workers at a Korean tertiary hospital. Scand J Infect Dis 2010;42:943–945.

35. Park Y, Kim SY, Kim JW, et al. Serial testing of healthcare workers for latent tuberculosis infection and long-term follow up for development of active tuberculosis. PLoS One 2018;13:e0204035.

36. Park SY, Lee EJ, Kim YK, et al. Aggressive contact investigation of in-hospital exposure to active pulmonary tuberculosis. J Korean Med Sci 2019;34:e58.

37. Korea Centers for Disease Control and Prevention. Manual of National Tuberculosis Control Osong. Cheongju (KR): Korea Centers for Disease Control and Prevention, 2018.

38. Cho KS. Tuberculosis control in the Republic of Korea. Epidemiol Health 2018;40:e2018036.

39. Schaaf HS, Collins A, Bekker A, Davies PD. Tuberculosis at extremes of age. Respirology 2010;15:747–763.

40. Pande JN, Singh SP, Khilnani GC, Khilnani S, Tandon RK. Risk factors for hepatotoxicity from antituberculosis drugs: a case-control study. Thorax 1996;51:132–136.

41. Umeki S. Age-related changes in the manifestations of tuberculosis: implications for drug therapy. Drugs Aging 1991;1:440–457.

42. Mok J, An D, Kim S, Lee M, Kim C, Son H. Treatment outcomes and factors affecting treatment outcomes of new patients with tuberculosis in Busan, South Korea: a retrospective study of a citywide registry, 2014–2015. BMC Infect Dis 2018;18:655.

43. Kim H, Kim HJ, Oh KH, Oh HW, Choi H. A pilot project of systematic tuberculosis screening in the elderly in a South Korean Province. Tuberc Respir Dis (Seoul) 2019;82:194–200.

44. Campbell JR, Dowdy D, Schwartzman K. Treatment of latent infection to achieve tuberculosis elimination in low-incidence countries. PLoS Med 2019;16:e1002824.

45. Li J, Yip BHK, Leung C, et al. Screening for latent and active tuberculosis infection in the elderly at admission to residential care homes: a cost-effectiveness analysis in an intermediate disease burden area. PLoS One 2018;13:e0189531.

46. Kim CJ, Kim Y, Bae JY, et al. Risk factors of delayed isolation of patients with pulmonary tuberculosis. Clin Microbiol Infect 2020;26:1058–1062.

47. Heo DH, Seo JW, Kim JH, et al. Delays in isolating patients admitted to hospital with pulmonary tuberculosis in Korea. J Korean Med Sci 2019;34:e270.

48. Han J, Nam BD, Park SY, et al. Risk factors for delayed isolation of patients with active pulmonary tuberculosis in an acute-care hospital. Sci Rep 2019;9:4849.

49. World Health Organization. Chest Radiography in Tuberculosis Detection: Summary of Current WHO Recommendations and Guidance on Programmatic Approaches. Geneva (CH): WHO, 2016.

50. Hwang EJ, Park S, Jin KN, et al. Development and validation of a deep learning-based automatic detection algorithm for active pulmonary tuberculosis on chest radiographs. Clin Infect Dis 2019;69:739–747.

51. Lee HS, Kee SJ, Shin JH, et al. Xpert MTB/RIF assay as a substitute for smear microscopy in an intermediate-burden setting. Am J Respir Crit Care Med 2019;199:784–794.

52. Park JS. Efficacy of induced sputum for the diagnosis of pulmonary tuberculosis in adults unable to expectorate sputum. Tuberc Respir Dis (Seoul) 2015;78:203–209.

53. Yong YK, Tan HY, Saeidi A, et al. Immune biomarkers for diagnosis and treatment monitoring of tuberculosis: current developments and future prospects. Front Microbiol 2019;10:2789.

54. Ahn B, Kim J, Yoo CG, Kim YW, Han SK, Yim JJ. Changes in diagnostic methods for pulmonary tuberculosis between 2005 and 2013. Tuberc Respir Dis (Seoul) 2015;78:227–231.